COSCIENS Biopharma Inc.
CSCI.TO
TSX
| 06/30/2025 | 03/31/2025 | ||||
|---|---|---|---|---|---|
| Revenue | 83.27% | -54.85% | |||
| Total Other Revenue | -- | -- | |||
| Total Revenue | 83.27% | -54.85% | |||
| Cost of Revenue | 67.93% | -16.97% | |||
| Gross Profit | 119.86% | -78.38% | |||
| SG&A Expenses | -9.88% | 6.55% | |||
| Depreciation & Amortization | -- | -- | |||
| Other Operating Expenses | -- | -- | |||
| Total Operating Expenses | -0.29% | -26.18% | |||
| Operating Income | 34.95% | -0.19% | |||
| Income Before Tax | 26.13% | 35.30% | |||
| Income Tax Expenses | -- | -- | |||
| Earnings from Continuing Operations | 26.10% | 45.70% | |||
| Earnings from Discontinued Operations | -- | -- | |||
| Extraordinary Item & Accounting Change | -- | -- | |||
| Minority Interest in Earnings | -- | -- | |||
| Net Income | 26.10% | 45.70% | |||
| EBIT | 34.95% | -0.19% | |||
| EBITDA | 37.24% | 7.55% | |||
| EPS Basic | 26.81% | 45.77% | |||
| Normalized Basic EPS | 26.83% | -28.02% | |||
| EPS Diluted | 26.81% | 45.77% | |||
| Normalized Diluted EPS | 26.83% | -28.02% | |||
| Average Basic Shares Outstanding | 0.96% | 0.13% | |||
| Average Diluted Shares Outstanding | 0.96% | 0.13% | |||
| Dividend Per Share | -- | -- | |||
| Payout Ratio | -- | -- | |||